Adverum Biotechnologies, Inc. ADVM
We take great care to ensure that the data presented and summarized in this overview for Adverum Biotechnologies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ADVM
View allLatest Institutional Activity in ADVM
Top Purchases
Top Sells
About ADVM
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Insider Transactions at ADVM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 02
2025
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
15,209
+0.55%
|
$60,836
$4.04 P/Share
|
|
Mar 31
2025
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
19,566
+0.71%
|
$78,264
$4.38 P/Share
|
|
Mar 27
2025
|
Braden Michael Leonard |
SELL
Open market or private purchase
|
Direct |
16,593
-10.48%
|
$82,965
$5.19 P/Share
|
|
Mar 26
2025
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Direct |
20,407
+14.01%
|
$102,035
$5.04 P/Share
|
|
Mar 20
2025
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
30,600
+1.11%
|
$153,000
$5.61 P/Share
|
|
Mar 19
2025
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.92%
|
$100,000
$4.94 P/Share
|
|
Mar 18
2025
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
62,341
+1.16%
|
$249,364
$4.67 P/Share
|
|
Feb 28
2025
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
85,068
+3.16%
|
$340,272
$4.6 P/Share
|
|
Feb 27
2025
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
86,802
+3.33%
|
$347,208
$4.46 P/Share
|
|
Feb 26
2025
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
164,886
+6.35%
|
$659,544
$4.01 P/Share
|
|
Feb 25
2025
|
Linda M Rubinstein CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
8,125
+29.6%
|
-
|
|
Feb 25
2025
|
Laurent Fischer CEO, PRESIDENT AND DIRECTOR |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+20.56%
|
-
|
|
Feb 25
2025
|
Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
8,125
+35.61%
|
-
|
|
Feb 25
2025
|
Rabia Gurses Ozden Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,125
+50.0%
|
-
|
|
Feb 25
2025
|
Peter Soparkar CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,125
+23.76%
|
-
|
|
Jul 30
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
85,800
+3.65%
|
$600,600
$7.15 P/Share
|
|
Jul 18
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
80,718
+3.57%
|
$726,462
$9.11 P/Share
|
|
Jul 17
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
135,546
+6.06%
|
$948,822
$7.75 P/Share
|
|
Feb 07
2024
|
Lupher, Jr. Mark L. |
BUY
Open market or private purchase
|
Direct |
130,000
+50.0%
|
$130,000
$1.35 P/Share
|
|
Feb 07
2024
|
James Paul Scopa |
BUY
Open market or private purchase
|
Direct |
100,000
+50.0%
|
$100,000
$1.35 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 62.5K shares |
|---|---|
| Open market or private purchase | 812K shares |
| Open market or private purchase | 16.6K shares |
|---|